In this analysis of 2-year retrospective cohort studies, we extracted data from the TriNetX electronic health records network, an international network of de-identified data from health-care records of approximately 89 million patients collected from hospital, primary care, and specialist providers (mostly from the USA, but also from Australia, the UK, Spain, Bulgaria, India, Malaysia, and Taiwan). The Lancet Regional Health – Western Pacific.The Lancet Regional Health – Southeast Asia.The Lancet Gastroenterology & Hepatology.With the goal to sequence 100,000 advanced cancer patients starting in 2017, the company's mission is to match patients to the right clinical trials and to accelerate the approval and availability of precision medicines for cancer. About Strata Oncology Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials. Rhodes and Flaherty are joined on Strata's Board of Directors by Jan Garfinkle (Arboretum Ventures), Nicole Walker (Baird Capital) and Jeff Williams, founder and CEO of NeuMoDx Molecular. Flaherty is a world leader in precision oncology clinical trials and Tomlins is an expert in tumor sequencing and molecular pathology. Rhodes, who is the former co-founder and CEO of Compendia Bioscience, a cancer genomics firm that was acquired in 2012 by Life Technologies, co-founded Strata Oncology in 2015 with oncologist Keith Flaherty, M.D., from Harvard Medical School and Massachusetts General, and pathologist Scott Tomlins, M.D., Ph.D., from the University of Michigan Medical School. 'Thermo Fisher is committed to enabling its growing list of strategic partners to drive the era of precision medicine through its targeted, next-generation sequencing technology, which will help laboratories and clinicians provide the best oncology treatment possible in the future,' said Joe Bernardo, president of Clinical Sequencing at Thermo Fisher. 'By providing no-cost tumor sequencing for 100,000 cancer patients, Strata intends to be the catalyst, helping patients find the right trials and helping pharma find the right patients.' Additionally, the company has entered into a strategic partnership with Thermo Fisher Scientific, which will serve as the technology provider and contribute Ion S5 XL next-generation sequencing systems, AmpliSeq technology, and Oncomine assays. 'For most cancer patients in the U.S., tumor sequencing is not standard of care, so patients remain unaware of their eligibility for promising precision medicine clinical trials,' said Dan Rhodes, Ph.D., Strata Oncology co-founder and CEO. Arboretum Ventures and Baird Capital co-led the financing, with additional funding provided by Strata's existing investor, Michigan eLab. The financing will fuel Strata's state-of-the-art tumor sequencing operation and implementation of the Strata Trial, a nation-wide effort aimed at substantially increasing the number of enrollments in precision medicine clinical trials.

Strata oncology